Processa Pharmaceuticals, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Processa Pharmaceuticals, Inc. (PCSA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $17.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-09-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-11-20
- Processa Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$25.00K.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $15.00K.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-03-31 was $27.00K, a 1829.95% increase year-over-year.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $17.00K, a 42.76% decline from fiscal 2015.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $29.70K.
- Processa Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$11.01K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$25.00K derived: sum of 2 quarters · filed 2017-11-20 | -$10.00K derived: sum of 3 quarters · filed 2017-11-20 | $17.00K 10-K · filed 2017-09-25 |
| 2016-09-30 | -$25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | -$10.00K derived: sum of 2 quarters · filed 2017-11-20 | $17.00K 10-Q · filed 2017-11-20 | $48.10K derived: sum of 4 quarters · filed 2017-11-20 |
| 2016-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-10-04 | $42.00K 10-Q · filed 2017-10-04 | $73.10K derived: sum of 3 quarters · filed 2017-10-04 | $73.10K derived: sum of 4 quarters · filed 2017-10-04 |
| 2016-03-31 | $27.00K 10-Q · filed 2017-10-04 | $58.10K derived: sum of 2 quarters · filed 2017-10-04 | $58.10K derived: sum of 3 quarters · filed 2017-10-04 | $55.30K derived: sum of 4 quarters · filed 2017-10-04 |
| 2015-12-31 | $31.10K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $31.10K derived: sum of 2 quarters · filed 2017-09-25 | $28.30K derived: sum of 3 quarters · filed 2017-09-25 | $29.70K 10-K · filed 2017-09-25 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | -$2.80K derived: sum of 2 quarters · filed 2017-09-08 | -$1.40K 10-Q · filed 2017-09-08 | |
| 2015-06-30 | -$2.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-30 | -$1.40K 10-Q · filed 2017-08-30 | ||
| 2015-03-31 | $1.40K 10-Q · filed 2017-08-07 | |||
| 2014-12-31 | -$11.01K 10-K · filed 2017-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |